Suppr超能文献

1980年以来的表面活性剂历史。

History of surfactant from 1980.

作者信息

Halliday Henry L

机构信息

Regional Neonatal Unit, Royal Maternity Hospital, and Department of Child Health, Queen's University of Belfast, Northern Ireland, UK.

出版信息

Biol Neonate. 2005;87(4):317-22. doi: 10.1159/000084879. Epub 2005 Jun 1.

Abstract

The first successful trial of surfactant treatment for respiratory distress syndrome (RDS) was reported in 1980. Since then there have been numerous randomised trials demonstrating first, the efficacy of surfactant treatment in reducing pulmonary air leaks and increasing survival and second, assessing various other aspects of therapy. These studies show that multiple doses may be needed if surfactant is used to treat established RDS but early or prophylactic treatment is superior for infants with gestational ages less than 30 weeks. Natural surfactants (containing proteins) are more effective than synthetic products (protein free), the latter now being infrequently used. Natural surfactants vary and should not be considered to be equivalent in their effects. A porcine surfactant (poractant alfa) acts more rapidly than a bovine preparation (beractant) in infants with moderate to severe RDS. A meta-analysis of 5 comparative studies suggests that a dose of 200 mg/kg of poractant alfa is associated with lower mortality compared with 100 mg/kg of beractant. Chronic lung disease remains a problem but it is hoped that early treatment with surfactant combined with extubation to continuous positive airway pressure will reduce this complication of prematurity. The newer synthetic surfactants, containing analogues of surfactant protein B or C, have undergone some trials for treatment of RDS but comparative studies which have just been published do not show that they are superior to existing natural surfactants. However, as they are more resistant to inactivation they may have a role in treatment of adult or acute RDS. The last 25 years have seen a large increase in basic science research on surfactants with determination of the structure and function of the four surfactant proteins probably being the most important advances. Future studies will focus on widening the indications for surfactant treatment, developing non-invasive means of administration and assessing the role of the newer synthetic surfactants.

摘要

1980年报道了首例成功使用表面活性剂治疗呼吸窘迫综合征(RDS)的试验。从那时起,已有大量随机试验,首先证明了表面活性剂治疗在减少肺漏气和提高生存率方面的疗效,其次评估了治疗的其他各个方面。这些研究表明,如果使用表面活性剂治疗已确诊的RDS,可能需要多次给药,但对于孕周小于30周的婴儿,早期或预防性治疗效果更佳。天然表面活性剂(含蛋白质)比合成产品(不含蛋白质)更有效,后者目前很少使用。天然表面活性剂各不相同,其效果不应被视为等同。在中重度RDS婴儿中,猪肺表面活性剂(固尔苏)的作用比牛肺表面活性剂(珂立苏)更快。一项对5项比较研究的荟萃分析表明,与100mg/kg的珂立苏相比,200mg/kg的固尔苏剂量与更低的死亡率相关。慢性肺病仍然是一个问题,但人们希望早期使用表面活性剂并结合拔管至持续气道正压通气将减少这种早产并发症。含有表面活性蛋白B或C类似物的新型合成表面活性剂已进行了一些治疗RDS的试验,但刚刚发表的比较研究并未表明它们优于现有的天然表面活性剂。然而,由于它们对失活更具抵抗力,它们可能在成人或急性RDS的治疗中发挥作用。在过去25年里,关于表面活性剂的基础科学研究大幅增加,确定四种表面活性蛋白的结构和功能可能是最重要的进展。未来的研究将集中在扩大表面活性剂治疗的适应症、开发非侵入性给药方法以及评估新型合成表面活性剂的作用。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验